Lindbrook Capital, LLC Bei Gene, Ltd. Transaction History

Lindbrook Capital, LLC

$1.09 Billion
Q4 2024

A detailed history of Lindbrook Capital, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 219 shares of BGNE stock, worth $49,649. This represents 0.0% of its overall portfolio holdings.

Number of Shares

219

Previous 207 5.8%

Holding current value

$49,649

Previous $46,000 13.04%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$174.72 - $246.04 $2,096 - $2,952	12 Added 5.8%	219 $40,000
Q1 2022 Apr 21, 2022	SELL	$146.52 - $269.56 $10,989 - $20,217	-75 Reduced 26.6%	207 $39,000
Q4 2021 Jan 18, 2022	SELL	$248.56 - $389.34 $7,953 - $12,458	-32 Reduced 10.19%	282 $76,000
Q3 2021 Nov 05, 2021	BUY	$249.6 - $403.14 $2,745 - $4,434	11 Added 3.63%	314 $114,000
Q2 2021 Jul 27, 2021	BUY	$292.75 - $367.01 $878 - $1,101	3 Added 1.0%	303 $104,000
Q4 2020 Jan 27, 2021	SELL	$221.31 - $316.61 $4,426 - $6,332	-20 Reduced 6.25%	300 $78,000
Q3 2020 Nov 03, 2020	BUY	$189.18 - $286.44 $10,594 - $16,040	56 Added 21.21%	320 $92,000
Q2 2020 Jul 27, 2020	BUY	$123.9 - $195.41 $27,505 - $43,381	222 Added 528.57%	264 $50,000
Q1 2020 Apr 22, 2020	BUY	$121.84 - $173.19 $5,117 - $7,273	42 New	42 $5,000
Q4 2019 Jan 27, 2020	SELL	$115.78 - $208.34 $6,367 - $11,458	-55 Closed	0 $0
Q2 2019 Jul 24, 2019	BUY	$113.99 - $146.86 $911 - $1,174	8 Added 17.02%	55 $6,000
Q1 2019 Apr 23, 2019	BUY	$122.82 - $151.83 $5,772 - $7,136	47 New	47 $6,000

Others Institutions Holding BGNE

# of Institutions

251

Shares Held

45.6M

Call Options Held

322K

Put Options Held

144K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.

Account

Lindbrook Capital, LLC Bei Gene, Ltd. Transaction History